Head-to-head Study of Erenumab Against Topiramate in Patients With Episodic and Chronic Migraine

Novartis Pharmaceuticals777 enrolled

Overview

This study used a single-cohort, 2-treatment arm, parallel-group randomized, double-blind, double-dummy design in adult patients with episodic migraine and chronic migraine, who had to be either naïve or not suitable for or could have failed up to three prophylactic treatments out of: propranolol/metoprolol, amitriptyline, flunarizine. Patients were stratified into groups according to their number of migraine days during the baseline period.

All patients completing the Baseline period and fulfilling baseline eligibility criteria were invited to participate to the Double-blind, double-dummy Treatment Epoch (DBTE, 24 weeks) . Eligible patients were randomized to one of two treatment arms. DBTE started with a titration phase for topiramate of a maximum of 6 weeks to determine the maximal tolerated dose and aimed to reach the recommended treatment dose of 100 mg according to the German SmPC. After the titration phase, maintenance phase started (18 weeks). Topiramate dose had to be maintained until the end of the DBTE. Erenumab dose at beginning of the DBTE was determined patient individually by the investigator based on the guidance provided in the SmPC and was either 70 mg or 140 mg. Dose escalation from 70 mg to 140 mg in case of insufficient response was considered at anytime during the DBTE. Dose reduction of topiramate and erenumab was not allowed during DBTE (Week 0 to Week 24). After Week 24 or if the patient discontinued study drug, a one week double-blind taper off phase followed to ensure proper down titration for topiramate. At the end of the DBTE (24 weeks) the final assessment occurred to address the objectives. A Follow-Up Visit 4 weeks after last study visit (or 8 weeks after last IMP injection for discontinued patients) was required as part of routine safety monitoring. The primary analysis was triggered when all patients had completed their respective last visit of the DBTE. The End of study occurred when the last patient completed last visit (LPLV).

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

PREVENTION

Masking

DOUBLE

Enrollment

777

Conditions

Migraine

Interventions

ErenumabBIOLOGICAL

70mg/1mL (70 mg) or 2x70mg/1mL (140 mg) in pre-filled syringe, administered every 4 weeks

TopiramateDRUG

Film-coated tablet taken orally: 25 mg administered once daily (first week of titration phase). After the first week, titration was done according to the summary of product characteristics (SmPC) in 25 mg increments each week and aimed to reach the recommended daily treatment dose of 100 mg (50/75/100 mg). 50/75/100 mg were administered twice daily during titration phase and maintenance phase.

Erenumab matching placeboBIOLOGICAL

Erenumab matching placebo pre-filled syringue administered every 4 weeks

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 Years

Medical Language ↔ Plain English

Key Inclusion Criteria: 1. Documented history of migraine in the 12 months prior to screen 2. at least 4 days per month of migraine symptoms 3. \>=80% diary compliance during the Baseline period 4. Patients must be either naïve or not suitable or have failed previous migraine prophylactic treatments Key Exclusion Criteria: 1. Older than 50 years of age at migraine onset 2. Pregnant or nursing 3. History of cluster or hemiplegic headache 4. History or evidence of major psychiatric disorder 5. Score of 19 or higher on Beck Depression Inventory (BDI)

Locations (79)

Outcomes

Primary Outcomes

Proportion of Patients With Treatment Discontinuation Due to an Adverse Event (AE) During the Double-blind Treatment Epoch/Period (DBTE)

The primary objective was to demonstrate the tolerability of 70 mg and 140 mg erenumab compared to topiramate in the highest tolerated dose assessed by the rate of patients discontinuing treatment due to AE during the double-blind epoch of the study.

Time frame: 24 Weeks

Secondary Outcomes

Number of Patients With at Least 50% Reduction From Baseline in Monthly Migraine Days (MMD) Over the Last Three Months (Month 4, 5, and 6)

The secondary objective of this study was to evaluate the effect of erenumab compared to topiramate on the proportion of patients with at least 50% reduction from baseline in MMDs. The Baseline period was defined as the period between Week -4 and the day prior to first dose. This was analyzed by logistic regression over the last 3 months (months 4, 5, and 6) of treatment. All the subjects' data collected regarding 50% response in MMD was used in the analysis regardless of whether subjects discontinue study treatment or not. Subjects with missing response information on this endpoint were imputed as non-response (non-responder imputation).

Time frame: Baseline, Last three months (month 4, 5, and 6)

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

Novartis Investigative Site

Stuttgart, Baden-Wurttemberg, Germany

Novartis Investigative Site

Marburg Wehrda, Germany, Germany

Novartis Investigative Site

Hanover, Lower Saxony, Germany

Novartis Investigative Site

Aachen, North Rhine-Westphalia, Germany

Novartis Investigative Site

Alzenau in Unterfranken, Germany

Novartis Investigative Site

Bad Homburg, Germany

Novartis Investigative Site

Bad Honnef, Germany

Novartis Investigative Site

Bad Saarow, Germany

Novartis Investigative Site

Bayreuth, Germany

Novartis Investigative Site

Bergen, Germany

...and 69 more locations